InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-13.3%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by KINGSLEY ALFRED D, Director. Officer active across 3 companies, notably Lineage Cell Therapeutics, Inc.. In total, 8 disclosures have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €13k. Activity tracked since 22 June 2021. The latest transaction was disclosed on 23 June 2023 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations8 total
20,000 shares0Common Stock, no par valueSEC:0001493152-23-022667:0
30,000 shares@ US$0.214947.0% of flowCommon Stock, no par valueSEC:0001493152-23-021531:0
Ideal exit: 10 Mar 2024 (T+270)
25,000 shares@ US$0.28553.0% of flowCommon Stock, no par valueSEC:0001493152-22-036605:0
Ideal exit: 18 Sept 2023 (T+270)
10,000 shares0Common Stock, no par valueSEC:0001493152-22-023383:0
10,000 shares0Common Stock, no par valueSEC:0001493152-22-019820:0
61,800 shares@ US$2.2050.0% of flowCommon Shares, no par valueSEC:0001493152-21-015072
61,800 shares@ US$2.200.028% mcap50.0% of flowCommon Shares, no par valueSEC:0001493152-21-015072:0
300,000 sharesCommon Shares, no par valueSEC:0001209191-16-093158:0
8 of 8 declarations
About KINGSLEY ALFRED D
Alfred D. Kingsley is a Director at Lineage Cell Therapeutics, Inc. He plays a key role in the governance and strategy of the company. Lineage Cell Therapeutics is a biopharmaceutical company focused on cell therapies. Alfred brings valuable expertise in the field, contributing to the company's direction and growth.
